Phaseline

Companies › United Immunity

United Immunity: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UI-102
TLR7/8 agonist encapsulated in Cholesteryl Pullulan Nanoparticle
TLR7, TLR8Phase 1Advanced CancerMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07605962UI-102Phase 1Advanced CancerOncologyMar 2030

Targets

TLR7 (1) TLR8 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune OX2 Therapeutics Primmune Therapeutics Solstice Oncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.